Tarsus Pharmaceuticals, Inc.
TARS
$79.44
-$0.53-0.66%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 118.70M | 102.66M | 78.34M | 66.41M | 48.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 118.70M | 102.66M | 78.34M | 66.41M | 48.12M |
| Cost of Revenue | 24.59M | 21.83M | 19.62M | 21.80M | 15.37M |
| Gross Profit | 94.10M | 80.83M | 58.72M | 44.61M | 32.75M |
| SG&A Expenses | 108.63M | 103.01M | 85.00M | 69.03M | 57.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 133.23M | 124.84M | 104.62M | 90.83M | 73.28M |
| Operating Income | -14.53M | -22.18M | -26.28M | -24.42M | -25.16M |
| Income Before Tax | -12.59M | -20.34M | -25.12M | -23.11M | -23.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.59M | -20.34M | -25.12M | -23.11M | -23.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.59M | -20.34M | -25.12M | -23.11M | -23.42M |
| EBIT | -14.53M | -22.18M | -26.28M | -24.42M | -25.16M |
| EBITDA | -14.07M | -21.73M | -25.82M | -23.99M | -24.88M |
| EPS Basic | -0.30 | -0.48 | -0.64 | -0.60 | -0.61 |
| Normalized Basic EPS | -0.18 | -0.30 | -0.42 | -0.33 | -0.38 |
| EPS Diluted | -0.30 | -0.48 | -0.64 | -0.60 | -0.61 |
| Normalized Diluted EPS | -0.18 | -0.30 | -0.42 | -0.33 | -0.38 |
| Average Basic Shares Outstanding | 42.61M | 42.36M | 39.35M | 38.56M | 38.38M |
| Average Diluted Shares Outstanding | 42.61M | 42.36M | 39.35M | 38.56M | 38.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |